The first clinical use of BioVentrix’s closed-chest Revivent-TC transcatherter ventricular enhancement system in the UK has taken place at Freeman Hospital, Newcastle-upon-Tyne.
The less invasive ventricular enhancement (LIVE) procedure, which uses this new transcatheter approach, is in a clinical trial throughout western Europe, and is used in the treatment of ischaemic cardiomyopathy.
The transcatheter procedure should reduce excessive volume and reshape the left ventricle (LV) by pulling the walls of the heart together with its proprietary micro-anchor pair implants. By remodelling the LV to a more normal shape and size, the implant is designed to improve pumping efficiency, decrease wall stress, and immediately reverse patient symptoms. The procedure was performed by interventional cardiologist Azfar Zaman, head of Structural Heart Development, and by cardiothoracic surgeon Stephan Schueler, head of the LVAD Program, both at Newcastle upon Tyne’s Freeman Hospital in the UK.
The device was successfully implanted with four micro-anchor pairs in a 62-year-old man suffering from ischaemic heart failure. The procedure achieved an approximate decrease of the Left Ventricular End Systolic Volume Index (LVESVI) by 25%.
“We are very excited about the outcome of this procedure and believe that this therapy should be strongly considered when evaluating options for treating these types of patients,” says Zaman.
“The TransCatheter delivery system, which utilises a combined endovascular approach in conjunction with the interventional cardiologist, allows for more ischaemic heart failure patients to be treated, and reduces procedural risk from prior therapy options such as surgical ventricular reconstruction. Most importantly, we can achieve significant LV volume reduction without having to open the patient’s chest or employ cardiopulmonary bypass,” adds Schueler.